In a recent study [83], 52 PCA patients underwent magnetic resonance imaging, fluorodeoxyglucose (FDG)-, amyloid-, and tau-positron emission tomography (tau-PET) scans, as well as a neuropsychological assessment. The gene discussed is MAPT; the disease is posterior cortical atrophy.